Skip to content

US · BCYC · BIOTECHNOLOGY

Bicycle Therapeutics plc (BCYC) intrinsic value and stock valuation

$2.90as of 2026-11-21 · Mkt cap 275.5M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bicycle Therapeutics plc DCF and intrinsic value

InvestorsCraft values BCYC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BCYC’s statements →

Bicycle Therapeutics plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, CAM CB22 3AT bicycletherapeutics.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$72.6M+47.5% 5y CAGRd
20162025
Net income
-$-218.96M
20162025
Free cash flow
-$-252.61M
20162025
Total equity
$610M+44.9% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$72.6M$35.3M$27M$14.5M$11.7M
Operating income-$-247.72M-$-209.87M-$-189.95M-$-116.65M-$-65.62M
Net income-$-218.96M-$-169.03M-$-180.66M-$-112.72M-$-66.82M
EPSd-$-3.16M-$-2.9M-$-5.08M-$-3.8M-$-2.67M
Operating cash flow-$-249.68M-$-164.72M-$-60.63M-$-86.11M-$-14.79M
Capital expenditure-$-2.36M-$-1.24M-$-2.93M-$-18.99M-$-2.03M
Free cash flow-$-252.61M-$-165.96M-$-63.56M-$-105.1M-$-16.82M
Total assets$717.6M$956.9M$595.3M$410.6M$479.8M
Total debt$17.5M$9.49M$45M$44.3M$44.3M
Net debt-$-610.59M-$-870.03M-$-481.47M-$-294.83M-$-394.34M
Total equity$610M$793.1M$370.9M$270.8M$346.3M
Cash and short-term investments$628.1M$879.5M$526.4M$339.2M$438.7M
Income statement
20252024202320222021
Revenue$72.6M$35.3M$27M$14.5M$11.7M
Cost of revenue$0.00$173M$156.5M$0.00$0.00
Gross profit$72.6M-$-137.69M-$-129.52M$14.5M$11.7M
Research and development expenses$240.3M$173M$156.5M$81.6M$44.9M
Selling, general and administrative expenses$80M$71.5M$59.8M$49.5M$32.4M
Other expenses$0.00-$-172.25M-$-155.9M$0.00$0.00
Operating expenses$320.3M$72.2M$60.4M$131.1M$77.3M
Cost and expenses$320.3M$245.2M$216.9M$131.1M$77.3M
Interest income$28.5M$34.3M$14M$5.76M$120K
Interest expense$210K$1.73M$3.26M$3.34M$2.98M
Depreciation and amortization$6.42M$7.18M$6.55M$3.69M$1.41M
Ebitda-$-212.18M-$-164.89M-$-169.4M-$-107.21M-$-64.09M
Operating income-$-247.72M-$-209.87M-$-189.95M-$-116.65M-$-65.62M
Total other income/expenses, net$28.9M$36.1M$10.7M$2.41M-$-2.86M
Income before tax-$-218.81M-$-173.8M-$-179.21M-$-114.24M-$-68.48M
Income tax expense$150K-$-4.76M$1.46M-$-1.52M-$-1.66M
Net income-$-218.96M-$-169.03M-$-180.66M-$-112.72M-$-66.82M
Weighted average shares outstanding$69.3M$58.2M$35.6M$29.7M$25.1M
Weighted average diluted shares outstanding$69.3M$58.2M$35.6M$29.7M$25.1M
Balance sheet
20252024202320222021
Cash and short-term investments$628.1M$879.5M$526.4M$339.2M$438.7M
Net receivables$35.6M$35.7M$24M$21.2M$11.9M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$682.9M$928.6M$561.9M$369.4M$458.6M
Property, plant and equipment, net$21.9M$17.2M$27.7M$32.8M$17.8M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$60K$550K$550K$0.00$0.00
Total non-current assets$34.7M$28.3M$33.5M$41.2M$21.2M
Total assets$717.6M$956.9M$595.3M$410.6M$479.8M
Accounts payable$9.67M$15.8M$13.1M$6.47M$2.72M
Short-term debt$2.76M$5.5M$4.88M$3.12M$2.38M
Deferred revenue$2.96M$10.2M$25M$20.4M$19.3M
Total current liabilities$57M$67.2M$69.5M$53.3M$36.2M
Long-term debt$14.8M$3.99M$40.1M$41.2M$42M
Deferred revenue, non-current$35.5M$91.5M$110.2M$41.5M$52.1M
Total non-current liabilities$50.6M$96.6M$154.9M$86.5M$97.3M
Capital lease obligations$14.8M$9.49M$9.38M$14M$14.5M
Total liabilities$107.6M$163.8M$224.4M$139.8M$133.5M
Common stock$890K$890K$550K$390K$380K
Retained earnings-$-899.75M-$-680.79M-$-511.76M-$-331.1M-$-218.38M
Accumulated other comprehensive income (loss)-$-3.5M$120K-$-1.3M$390K-$-3.39M
Total equity$610M$793.1M$370.9M$270.8M$346.3M
Total investments$60K$550K$550K$0.00$0.00
Total debt$17.5M$9.49M$45M$44.3M$44.3M
Net debt-$-610.59M-$-870.03M-$-481.47M-$-294.83M-$-394.34M
Cash flow statement
20252024202320222021
Net income-$-218.96M-$-169.03M-$-180.66M-$-112.72M-$-66.82M
Depreciation and amortization$6.42M$7.17M$6.55M$3.69M$1.41M
Stock-based compensation$39.5M$38.1M$32.5M$26.8M$12.1M
Change in working capital-$-75.75M-$-33.46M$76.7M$670K$38.1M
Accounts receivable$2.89M-$-11.95M-$-1.2M-$-11.35M$4.54M
Inventory$0.00$0.00$0.00$0.00-$-4.79M
Accounts payable-$-6.87M$3.1M$8M$2.56M$1.2M
Net cash provided by operating activities-$-249.68M-$-164.72M-$-60.63M-$-86.11M-$-14.79M
Investments in property, plant and equipment-$-2.36M-$-1.24M-$-2.93M-$-18.99M-$-2.03M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-2.35M-$-1.24M-$-2.93M-$-18.99M-$-2.03M
Common stock issued$40K$544.1M$249.3M$5.7M$298.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-130K$519.8M$250M$6.69M$320.7M
Net change in cash-$-251.35M$353.1M$187.8M-$-99.53M$302.7M
Cash at end of period$628.7M$880.1M$527M$339.2M$438.7M
Operating cash flow-$-249.68M-$-164.72M-$-60.63M-$-86.11M-$-14.79M
Capital expenditure-$-2.36M-$-1.24M-$-2.93M-$-18.99M-$-2.03M
Free cash flow-$-252.61M-$-165.96M-$-63.56M-$-105.1M-$-16.82M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bicycle Therapeutics plc

        Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.

        CEO
        Kevin Lee
        Employees
        288
        Beta
        1.55

        Explore

        Frequently asked questions

        What is the intrinsic value of Bicycle Therapeutics plc (BCYC)?

        Bicycle Therapeutics plc (BCYC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BCYC undervalued?

        BCYC trades at a price of $2.90 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.